
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+6
We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical...
Nécrose régulée,insuffisance rénale aiguë,insuffisance hépatique aiguë,ferroptose,nécroptose,intoxication médicamenteuse,néphrotoxicité,hépatotoxicité,maladies neurodégénératives,paracetamol,and cisplatine
Seabelife biotech operates in the Biotechnology research industry.
Seabelife biotech's revenue is 1m - 10m
Seabelife biotech has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.